Tilray Stock in 2026: Strong Earnings Report Sparks Investor Optimism

Tilray’s Q2 2026: Breaking Down the Numbers

Tilray’s second-quarter results for fiscal 2026 revealed a mixed but promising picture. The company reported $218 million in revenue, surpassing analyst estimates by $6.4 million. Key highlights include a 36% surge in international medical cannabis sales and a narrowed non-GAAP loss per share of -$0.02. While profitability remains elusive, the reaffirmed EBITDA guidance for 2026 suggests management confidence in its operational strategy. The stock, which had been under pressure, stabilized at $9.18 on Nasdaq and €7.88 on Tradegate post-announcement.

What Drove Tilray’s Growth?

The standout performer was Tilray’s international medical cannabis division, which now boasts an annualized revenue run-rate of $150 million. Europe’s gradual regulatory easing has been a tailwind, while Canada’s recreational market saw modest 6% growth. Analyst Kristoffer Inton of Morningstar noted that Tilray’s aggressive expansion in higher-margin medical markets contrasts with competitors scaling back—a strategic edge that could pay off long-term.

Market Reaction: A Turning Point?

After a 37.6% decline over the past year (in euro terms), Tilray’s stock showed signs of bottoming out. The Q2 report challenged bearish narratives tied to U.S. regulatory delays and Canadian margin pressures. Technical traders are eyeing the $9.18 level as critical: Holding above it could trigger short-term buying, while a drop might retest yearly lows. "The valuation disconnect between price and revenue is becoming hard to ignore," observed the BTCC research team.

Challenges and Opportunities Ahead

Tilray’s path hinges on two factors: executing its medical cannabis expansion (particularly in Europe) and navigating U.S. regulatory shifts. While federal cannabis reclassification remains uncertain, progress could turbocharge Tilray’s existing infrastructure. Meanwhile, cost discipline must continue—Q2’s improved loss per share suggests efforts are working, but sustainability is key.

FAQ: Your Tilray Stock Questions Answered

Is Tilray profitable yet?

No, but losses are shrinking. Q2’s non-GAAP loss per share improved to -$0.02, aided by cost cuts.

Why did medical cannabis grow 36%?

Europe’s regulatory easing and Tilray’s early investments in production/distribution are paying off.

Should I buy Tilray stock now?

This article does not constitute investment advice. Consider growth potential versus regulatory risks.